Unique ID issued by UMIN | UMIN000049442 |
---|---|
Receipt number | R000055423 |
Scientific Title | Study on monoamine oxidase B (MAO-B) distribution differences associated with MAO-B inhibitors and smoking in Parkinson's disease: SMBT-1 PET study |
Date of disclosure of the study information | 2022/12/01 |
Last modified on | 2023/05/09 18:08:17 |
Study on monoamine oxidase B (MAO-B) distribution differences associated with MAO-B inhibitors and smoking in Parkinson's disease
MAO-B research in Parkinson's disease
Study on monoamine oxidase B (MAO-B) distribution differences associated with MAO-B inhibitors and smoking in Parkinson's disease: SMBT-1 PET study
MAO-B research in Parkinson's disease: SMBT-1 PET study
Japan |
Parkinson's disease (PD)
Neurology | Geriatrics |
Others
NO
To elucidate the pathophysiological mechanism of PD by using [18F]SMBT-1 PET examinations, as well as to elucidate the effects of smoking and MAO-B inhibitors by using PET examinations.
Others
To examine the differences of PET accumulations
SUV ratio (SUVR)
Interventional
Factorial
Non-randomized
Open -no one is blinded
No treatment
5
Diagnosis
Medicine |
To conduct PET examinations using the following tracers: 18F-SMBT-1
To examine the effects of the following tracers on 18F-SMBT-1 PET: rasagiline
To examine the effects of the following tracers on 18F-SMBT-1 PET: selegiline
To examine the effects of the following tracers on 18F-SMBT-1 PET: safinamide
Effects of habitual smoking
50 | years-old | <= |
90 | years-old | >= |
Male and Female
Parkinson's disease (PD) patients (non-smokers):
(1) Informed consent by the participant or by the substitues (native Japanese)
(2) Ages: basically 50 to 90 years old
(3) Fulfilling the conditions of PD
(4) No history of smoking at least 1 year before entry
(5) Those who can tolerate PET examination of up to 90 mins
Parkinson's disease (PD) patients (non-smokers and plan of MAO-B inhibitor treatment):
(1) Informed consent by the participant or by the substitues (native Japanese)
(2) Ages: basically 50 to 90 years old
(3) Fulfilling the conditions of PD and having the plan of MAO-B inhibitor treatment (should be before starting the treatment)
(4) No history of smoking at least 1 year before entry
(5) Those who can tolerate PET examination of up to 90 mins
Parkinson's disease (PD) patients (smokers):
(1) Informed consent by the participant or by the substitues (native Japanese)
(2) Ages: basically 50 to 90 years old
(3) Fulfilling the conditions of PD
(4) Habitual smokers or having history of smoking at least 7 days before the entry
(5) Those who can tolerate PET examination of up to 90 mins
Healthy controls (non-smokers):
(1) Informed consent by the participant or by the substitues (native Japanese)
(2) Ages: basically 50 to 90 years old
(3) Habitual smoking or history of smoking within 7 days of PET examination
(4) Those who can tolerate PET examination of up to 90 mins
Healthy controls (non-smokers):
(1) Informed consent by the participant or by the substitues (native Japanese)
(2) Ages: basically 50 to 90 years old
(3) Habitual smoking or history of smoking within 7 days of PET examination
(4) Those who can tolerate PET examination of up to 90 mins
Healthy controls (smokers):
(1) Informed consent by the participant or by the substitues (native Japanese)
(2) Ages: basically 50 to 90 years old
(3) Habitual smoking or history of smoking within 7 days of PET examination
(4) Those who can tolerate PET examination of up to 90 mins
(1) Administration of irreversible MAO-B inhibitors, Habitual smoking (within 1 year of entry)
(2) Being in the period of pregnancy, possible pregnancy, breast feeding, within 28 days after child birth
(3) Severe allergic reactions to drugs and foods
(4) Psychiatric disorders, which may make the participation to this study difficult
(5) Taboo conditions for MRI examinations (cardiac pacemaker, intracorpoporial metals, etc. to be checked with questionnaire in advance)
(6) Systemic circulatory and metabolic disorders as well as organ dysfuctions, such as diabetes melitus, hypertension, endocrinolog ical disorders, congestive heart failure, angina petoris, severe renal dysfunctions with Ccr<30mL/min or under plasmapheresis)
(7) Past history of malignant diseases within 1 year of entry
(8) Any sociomedial conditions, which may make the participation to this study difficult
57
1st name | Manabu |
Middle name | |
Last name | Tashiro |
Cyclotron and Radioisotope Center, Tohoku University
Division of Cyclotron Nuclear Medicine
980-8578
Cyclotron and Radioisotope Center, Tohoku University
0227957797
mtashiro@tohoku.ac.jp
1st name | Kotaro |
Middle name | |
Last name | Hiraoka |
Cyclotron and Radioisotope Center, Tohoku University
Division of Cyclotron Nuclear Medicine
980-8578
6-3 AzaAoba, Aramaki, Aoba-ku, Sendai
+81227957802
khiraoka@cyric.tohoku.ac.jp
Cyclotron and Radioisotope Center, Tohoku University
JSPS
Other
Ethics Committee Tohoku University Hospital
Seiryo-machi 1-1, Aramaki, Aoba-ku, Sendai
022-717-8654
ec@rinri.hosp.tohoku.ac.jp
NO
2022 | Year | 12 | Month | 01 | Day |
Unpublished
Open public recruiting
2022 | Year | 10 | Month | 01 | Day |
2022 | Year | 12 | Month | 07 | Day |
2022 | Year | 12 | Month | 01 | Day |
2025 | Year | 03 | Month | 31 | Day |
2022 | Year | 11 | Month | 06 | Day |
2023 | Year | 05 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055423
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |